Upadacitinib Induction Therapy Shows Favorable Outcomes in Moderate to Severe Crohn Disease
The patient cohorts were well-balanced at baseline, and, overall, 45.4% had a history of biologic therapy failure.
Diagnosis & Disease Information
Ustekinumab Concentrations Linked to Crohn Disease Radiologic, Biomarker Outcomes
Although ustekinumab is a common therapy used to treat CD, no serum concentrations that associate with outcomes have been established.
Earlier Initiation of Biologic Therapy Reduces Crohn Disease Complications
Biologics target inflammatory pathways, allowing for mucosal healing with the end goal of achieving clinical remission.
Insurance Companies Have Poor Adherence to Guidelines for UC, CD
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
Switching Biologic Treatments in Crohn Disease Linked to Increased Health Care Costs
Kaplan-Meier analyses were used to estimate the mean time to treatment switch, and all-cause health care resource use and costs (2020 $US) were compiled and compared for the 2 cohorts.
July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
AbbVie Seeks Crohn Disease Indication for Upadacitinib
The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.
Natalizumab Biosimilar to Get FDA Review for MS, Crohn Disease Indications
The application is under review for relapsing forms of multiple sclerosis and Crohn disease.
FDA to Review Biosimilar Hyrimoz High Concentration Formulation
The sBLA is supported by data from a phase 1 pharmacokinetics bridging study comparing Hyrimoz 50mg/mL and citrate-free Hyrimoz HCF.
New Indication: Skyrizi for Crohn Disease
Skyrizi is now approved for the treatment of moderately to severely active Crohn disease in adults.
